OCUL — Ocular Therapeutix Cashflow Statement
0.000.00%
- $2.50bn
- $2.18bn
- $63.72m
Annual cashflow statement for Ocular Therapeutix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -156 | -6.55 | -71 | -80.7 | -194 |
| Depreciation | |||||
| Non-Cash Items | 98.1 | -58.5 | 7.98 | 14.9 | 65.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.18 | -2.9 | 1.35 | -7.41 | -10.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -53.6 | -65.5 | -59.6 | -70.2 | -135 |
| Capital Expenditures | -0.841 | -1.19 | -3.71 | -6.09 | -1.29 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.841 | -1.19 | -3.71 | -6.09 | -1.29 |
| Financing Cash Flow Items | — | — | — | -5.18 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 228 | 2.85 | 1.45 | 170 | 332 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 174 | -63.9 | -61.9 | 93.5 | 196 |